Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SNAP-tag based agents for preclinical in vitro imaging in malignant diseases.
Amoury M, Blume T, Brehm H, Niesen J, Tenhaef N, Barth S, Gattenlöhner S, Helfrich W, Fitting J, Nachreiner T, Pardo A. Amoury M, et al. Among authors: helfrich w. Curr Pharm Des. 2013;19(30):5429-36. doi: 10.2174/13816128113199990405. Curr Pharm Des. 2013. PMID: 23431985
Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Amoury M, Kolberg K, Pham AT, Hristodorov D, Mladenov R, Di Fiore S, Helfrich W, Kiessling F, Fischer R, Pardo A, Thepen T, Hussain AF, Nachreiner T, Barth S. Amoury M, et al. Among authors: helfrich w. Cancer Lett. 2016 Mar 28;372(2):201-9. doi: 10.1016/j.canlet.2016.01.027. Epub 2016 Jan 21. Cancer Lett. 2016. PMID: 26806809
A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
Amoury M, Mladenov R, Nachreiner T, Pham AT, Hristodorov D, Di Fiore S, Helfrich W, Pardo A, Fey G, Schwenkert M, Thepen T, Kiessling F, Hussain AF, Fischer R, Kolberg K, Barth S. Amoury M, et al. Among authors: helfrich w. Int J Cancer. 2016 Aug 15;139(4):916-27. doi: 10.1002/ijc.30119. Epub 2016 Apr 15. Int J Cancer. 2016. PMID: 27037627 Free article.
CD20-selective inhibition of CD47-SIRPα "don't eat me" signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab.
van Bommel PE, He Y, Schepel I, Hendriks MAJM, Wiersma VR, van Ginkel RJ, van Meerten T, Ammatuna E, Huls G, Samplonius DF, Helfrich W, Bremer E. van Bommel PE, et al. Among authors: helfrich w. Oncoimmunology. 2017 Oct 31;7(2):e1386361. doi: 10.1080/2162402X.2017.1386361. eCollection 2018. Oncoimmunology. 2017. PMID: 29308308 Free PMC article.
143 results